Overview

Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of Bictegravir/FTC/TAF in patients with less of 100 days post HIV infection
Phase:
Phase 2
Details
Lead Sponsor:
Anna Cruceta
Treatments:
Emtricitabine
Tenofovir